/

LXRX

Lexicon Pharmaceuticals, Inc.Closed

1.61−0.04 −2.42%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.61 0.00%

Open

1.65

Prev close

1.65

Day range

1.591.66

52-week range

1.102.68

Volume

2.05M0.70×

Mkt cap

716.38M

P/E ttm

—

Fwd P/E

-8.45

EPS ttm

-0.1600

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−39.93%

Price Chart

Yahoo Finance · delayed

LXRXOct 13, 2026O 1.65H 1.66L 1.59C 1.61−0.04 (−2.42%)Vol 2.05M

SMA 502.11
SMA 2001.86

1Y change +8.05% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LXRX Lexicon Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.00%
1 month: −19.50%
3 months: −24.06%
6 months: −8.00%
Year to date: +40.00%
1 year: +11.81%

Valuation & ownership

Market cap: 716.38M
Enterprise value: 585.01M
P/E (ttm): —
Forward P/E: -8.45
PEG ratio: -13.77
Price / book: 4.11
Price / sales (ttm): 17.28
EV / EBITDA: -10.83
EPS (ttm): -0.1600
EPS (forward): -0.1906
Beta (5y monthly): 1.08
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 444.96M
Float: 218.99M
Short % of float: 10.94%
Short ratio (days): 7.60
Held by insiders: 1.12%
Held by institutions: 83.89%
Avg volume (3m): 2.92M
50-day average: 2.13
200-day average: 1.86
52-week change: +11.81%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 26.0
vs 50-day SMA: −23.85%
vs 200-day SMA: −13.56%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.33%
Realised vol (20d, ann.): 58.8%
From 52-week high: −39.93%
From 52-week low: +46.36%

ANR

Analyst Consensus

6 analysts

Consensus

—

Mean target

4.55

+182.40% implied

Low 2.00Median 4.55High 8.00

Recommendation trend

Now4 / 2 / 0
1m ago3 / 2 / 0

DES

About Lexicon Pharmaceuticals, Inc.

Yahoo Finance profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 81
Headquarters: The Woodlands, TX, United States
Website: lexpharma.com
Officers: Dr. Michael S. Exton Ph.D. CEO & Director
Mr. Scott M. Coiante Senior VP & CFO
Mr. Brian T. Crum

SEAS

Seasonality · LXRX

2007–2026 · monthly returns

Strongest month Jun +5.33%Weakest month Mar −2.87%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.9	26.7	6.1	3.2	35.4	10.1	-3.8	-2.6	-16.4	-14.4			+40.0%
2025	2.7	-7.9	-34.3	58.7	-13.7	50.8	12.6	2.8	22.7	2.2	3.6	-19.6	+55.4%
2024	22.2	33.2	-3.6	-35.8	10.4	-1.2	33.9	-23.1	-9.2	24.2	-59.0	-7.5	−51.6%
2023	17.3	0.4	8.0	-1.6	38.1	-30.6	-12.2	-14.4	-36.6	13.8	-14.5	44.3	−19.9%
2022	-19.5	-34.7	1.0	-13.4	-2.2	5.1	28.0	15.5	-12.7	-10.4	-0.5	-10.7	−51.5%
2021	131.3	-9.1	-18.4	-17.2	-9.7	4.6	-22.9	33.3	1.9	10.0	-13.4	-14.0	+15.2%
2020	-25.5	-10.0	-29.9	-3.1	1.1	4.7	-3.0	-9.8	-17.7	-22.9	37.8	123.5	−17.6%
2019	-28.8	12.5	4.5	4.3	-7.2	16.9	-78.5	-2.2	128.0	23.3	-4.9	17.6	−37.5%
2018	11.1	-21.4	-0.7	-3.7	40.6	3.4	-0.2	-3.4	-7.8	-26.6	3.4	-18.0	−32.8%
2017	3.6	11.9	-10.6	8.9	-11.3	18.8	-0.9	-7.1	-18.8	-17.1	0.3	-3.3	−28.6%
2016	-23.4	-8.3	27.9	15.6	2.9	1.0	13.7	-15.0	30.2	-17.9	2.7	-9.2	+3.9%
2015	0.0	3.3	0.0	6.4	0.4	14.5	4.8	41.5	-10.1	-11.5	44.7	-3.3	+108.9%
2014	2.2	-2.7	-3.4	-11.0	-14.3	22.0	-8.7	3.4	-7.2	2.8	-29.7	-10.8	−49.4%
2013	-3.6	-7.5	10.7	-9.2	20.2	-8.8	14.3	0.4	-4.4	0.8	0.0	-25.0	−18.6%
2012	12.4	17.2	9.4	-12.9	-1.9	41.5	7.6	-7.4	3.6	-8.6	-18.9	28.5	+71.3%
2011	17.4	14.8	-13.4	0.0	-3.0	8.0	-4.5	-19.0	-32.4	31.5	-3.3	10.3	−10.4%
2010	4.7	0.6	-16.8	7.4	-8.1	-12.9	18.0	-4.6	11.1	10.6	-22.6	5.1	−15.3%
2009	-15.0	-22.7	18.5	0.9	26.4	-10.8	7.3	13.5	41.1	-38.5	19.1	9.0	+21.4%
2008	-21.8	-21.5	8.6	2.0	2.4	-24.2	53.7	-24.4	-4.3	-11.8	8.9	-18.1	−53.8%
2007	5.3	8.7	-12.1	-3.3	-7.1	-1.5	0.6	-2.5	9.8	4.3	-3.9	-12.7	−16.1%

INSD

Insider Activity · LXRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 2, 2026	Sobecki Christopher JDirector	—	89.3K	—
Jun 2, 2026	Debbane RaymondDirector	—	89.3K	—
Jun 2, 2026	Swain Judith LDirector	—	89.3K	—
Jun 2, 2026	Sullivan Diane EDirector	—	89.3K	—
Jun 2, 2026	Cheung IvanDirector	—	89.3K	—
Jun 2, 2026	Barker Samuel LDirector	—	89.3K	—
Jun 2, 2026	Amouyal PhilippeDirector	—	89.3K	—
Apr 29, 2026	Artal Participations S.A.R.L.Director and Beneficial Owner of more than 10% of a Class of Security	—	20.42M	—
Feb 26, 2026	Coiante Scott MChief Financial Officer	—	160.2K	—
Feb 26, 2026	Crum Brian TGeneral Counsel	—	273K	—
Feb 26, 2026	Defrancesco LisaOfficer	—	152.9K	—
Feb 26, 2026	Granowitz Craig B. M.D., Ph.D.Officer	—	312.3K	—
Feb 26, 2026	Mcdermott WendyOfficer	—	224.4K	—
Feb 26, 2026	Exton MichaelChief Executive Officer	—	503.3K	—
Feb 26, 2026	Martens Rachel YapOfficer	—	67.1K	—
Feb 26, 2026	Gopinathan SumaOfficer	—	100K	—
Feb 24, 2026	Debbane RaymondDirector	Purchase at price 1.49 per share.	2K	$2.98K
Feb 22, 2026	Debbane RaymondDirector	Purchase at price 1.47 per share.	100K	$147.00K
Feb 19, 2026	Debbane RaymondDirector	Purchase at price 1.44 - 1.48 per share.	150K	$219.75K
Feb 17, 2026	Debbane RaymondDirector	Purchase at price 1.31 - 1.32 per share.	268.5K	$352.89K

13F

Investors Holding LXRX

latest 13F filings of 29 followed managers

Investors holding LXRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.7M	0.00%	1.13M	−30%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

LXRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LXRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lexicon Pharmaceuticals, Inc.

Seasonality · LXRX

Insider Activity · LXRX

Congress Trades · LXRX

Investors Holding LXRX

Investors Holding LXRX

Congress Trades · LXRX

Insider Activity · LXRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lexicon Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News

Seasonality · LXRX